Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Compounds to improve disease control in advanced breast cancer

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 1 Oct 2009

Views: 8570

Rating:

Save

Dr Peyman Hadji - Head of the Department of Endocrinology, Osteoporosis and Reproductive Medicine at Philipps-University of Marburg, Germany

Expert interview with Dr. Peyman Hadji, M.D conducted by Prof Gordon McVie. Compounds to improve disease control in Advanced Breast Cancer
To view or download the slides click here

Categories:
Breast
Drug development

Related Videos

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Metastatic bone disease: Importance of bone-targeted agents

Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert...

Metastatic bone disease: Importance of bone-targeted agents ( Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert Coleman - The University of Sheffield, Sheffield, UK )

Choosing Wisely in implementing prevention, screening and early detection...

Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda

Choosing Wisely in implementing prevention, screening and early detection programs in Africa ( Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda )

Overview of the management of HER2-low breast cancer patients

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Overview of the management of HER2-low breast cancer patients ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Updates on HER2-low breast cancer

Prof Sana Al Sukhun - University of Jordan, Amman, Jordan

Updates on HER2-low breast cancer ( Prof Sana Al Sukhun - University of Jordan, Amman, Jordan )

Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Novel antibody-drug conjugates (ADCs) technologies for management of mBC ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Survival outcomes in randomised controlled trials with first-line CDK4/6i in...

Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland

Survival outcomes in randomised controlled trials with first-line CDK4/6i in HR+/HER2-Ve breast cancer ( Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland )

Spindle cell lesions of the breast

Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland

Spindle cell lesions of the breast ( Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland )

Management of HER2 positive metastatic breast cancer treatment algorithm

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA

Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )

More from ecancer